论文部分内容阅读
目的:进一步对肠炎康联合美沙拉嗪治疗溃疡性结肠炎的安全性进行分析和探讨。方法:选取我院于2012年10月-2014年10月期间收治的100例溃疡性结肠炎患者,将其作为本次的研究对象,并分成对照组和观察组,每组各50例,对照组患者给予美沙拉嗪,观察组患者给予肠炎康联合美沙拉嗪,比较两组患者的临床治疗效果。结果:经过治疗后,两组患者的病情均得到不同程度改善,其中观察组总有效人数49例,总有效率为98%,对照组总有效人数39例,总有效率为78%,比较两组患者的治疗效果差异明显(P<0.05),具有统计学意义,此外,患者在治疗过程中没有出现较为明显的不良反应。结论:在溃疡性结肠炎患者的治疗过程中,肠炎康联合美沙拉嗪能够有效缓解患者的各临床症状,提高患者的治疗效果,患者的不良反应较少,具有一定的安全性,在临床上具有极为重要的意义,今后值得推广和应用。
OBJECTIVE: To further analyze the safety of enteritis combined with mesalazine in the treatment of ulcerative colitis. Methods: One hundred patients with ulcerative colitis treated in our hospital from October 2012 to October 2014 were selected as the study subjects and divided into control group and observation group, with 50 cases in each group. The control group The patients were given mesalazine, the patients in the observation group were given enteric-yankang combined with mesalazine, and the clinical effects of the two groups were compared. Results: After treatment, the two groups of patients were improved to varying degrees, of which the total effective observation group 49 cases, the total effective rate was 98%, the control group, the total effective number 39 cases, the total effective rate was 78% There was significant difference in the treatment effect between the two groups (P <0.05), which was statistically significant. In addition, there were no obvious adverse reactions in the course of treatment. Conclusion: In the treatment of patients with ulcerative colitis, enteric-Kang United Mesalazine can effectively alleviate the clinical symptoms of patients and improve the patient’s treatment, patients with less adverse reactions, with a certain degree of safety, clinically It is of great importance and should be promoted and applied in the future.